BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23579222)

  • 1. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
    Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
    Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
    Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
    J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA; Aksoy S; Zengin N; Altundag K
    J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
    Forero-Torres A; Saleh MN; Galleshaw JA; Jones CF; Shah JJ; Percent IJ; Nabell LM; Carpenter JT; Falkson CI; Krontiras H; Urist MM; Bland KI; De Los Santos JF; Meredith RF; Caterinicchia V; Bernreuter WK; O'Malley JP; Li Y; LoBuglio AF
    Clin Breast Cancer; 2010 Aug; 10(4):275-80. PubMed ID: 20705559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
    Viale G; Regan MM; Dell'Orto P; Mastropasqua MG; Maiorano E; Rasmussen BB; MacGrogan G; Forbes JF; Paridaens RJ; Colleoni M; Láng I; Thürlimann B; Mouridsen H; Mauriac L; Gelber RD; Price KN; Goldhirsch A; Gusterson BA; Coates AS;
    Ann Oncol; 2011 Oct; 22(10):2201-7. PubMed ID: 21335417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH; Kang MJ; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim SB
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.
    Palmieri C; Cleator S; Kilburn LS; Kim SB; Ahn SH; Beresford M; Gong G; Mansi J; Mallon E; Reed S; Mousa K; Fallowfield L; Cheang M; Morden J; Page K; Guttery DS; Rghebi B; Primrose L; Shaw JA; Thompson AM; Bliss JM; Coombes RC
    Breast Cancer Res Treat; 2014 Dec; 148(3):581-90. PubMed ID: 25395314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
    Carpenter R; Doughty JC; Cordiner C; Moss N; Gandhi A; Wilson C; Andrews C; Ellis G; Gui G; Skene AI
    Breast Cancer Res Treat; 2014 Apr; 144(3):569-76. PubMed ID: 24562823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
    Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M
    Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.